Personalized prescription of ACEI/ARBs for hypertensive COVID-19 patients
The COVID-19 pandemic has prompted an international effort to develop and repurpose medications and procedures to effectively combat the disease. Several groups have focused on the potential treatment utility of angiotensin-converting-enzyme inhibitors (ACEIs) and angiotensin-receptor blockers (ARBs...
Автори: | Bertsimas, D, Borenstein, A, Mingardi, L, Nohadani, O, Orfanoudaki, A, Stellato, B, Wiberg, H, Sarin, P, Varelmann, DJ, Estrada, V, Macaya, C, Gil, IJN |
---|---|
Формат: | Journal article |
Мова: | English |
Опубліковано: |
Springer Nature
2021
|
Схожі ресурси
Схожі ресурси
-
Personalized prescription of ACEI/ARBs for hypertensive COVID-19 patients
за авторством: Bertsimas, Dimitris, та інші
Опубліковано: (2021) -
Effect of ACEi and ARBs vs Non ACEi/ARBs in Hypertension with Respect to Renal Outcomes in COVID-19 Infection: A Retrospective Cohort Study
за авторством: S Ravitej, та інші
Опубліковано: (2022-11-01) -
Association of ACEi/ARB Use and Clinical Outcomes of COVID-19 Patients With Hypertension
за авторством: Jing Ma, та інші
Опубліковано: (2021-05-01) -
ACEIs and ARBs and Their Correlation with COVID-19: A Review
за авторством: Yehualashet AS, та інші
Опубліковано: (2020-09-01) -
The Potential Role of ACEi and ARBs in COVID-19; A Perspective
за авторством: Ahmad Hammad Hassan
Опубліковано: (2020-12-01)